When Science Becomes Personal: Adam Crystal on ALS, Drug Discovery, and Why This Moment Matters

For Adam Crystal, science has never been abstract.

Trained as a neuroscientist, shaped as a medical oncologist, and now leading oncology drug development as President of Research and Development at Tango Therapeutics, Adam has spent his career translating complex biology into medicines that can meaningfully change the course of disease. For years, his work lived at the theoretical intersection of rigor, probability, and patience. Then ALS entered his family’s life, and the distance between professional expertise and personal reality disappeared.

Adam’s mother, Judy, was diagnosed with ALS in late 2025. The diagnosis came quickly, but in hindsight, signs had been there. What began as subtle fatigue and slight changes in speech progressed into clear motor challenges. As a family of physicians, they recognized what was unfolding even before the words were spoken aloud.

Adam said the moment his father, a neurologist, first voiced the concern remains etched in his memory. What followed was not confusion about the disease itself, but a reckoning with what ALS actually means for families living inside it.

Sadly, Judy passed away in March 2026. This ALS Awareness Month, Adam is going “all in” for ALS research by sharing his personal experience with the disease and his professional outlook on how we move the ALS field forward.

A career built on translation

Adam’s path into industry was not linear, but it was deliberate. Early in his career, he realized that while academic medicine offered rigor and innovation, it did not offer the pace or scale of impact he was seeking. Industry, once opaque from the outside, became the place where his training could be most effectively deployed.

He said that what ultimately distinguished his career trajectory was his depth of scientific understanding. While many physicians enter drug development with depth of academic clinical trial experience, Adam brought with him an unusually strong command of underlying biology. That fluency allowed him to see drug development end to end, from molecular mechanism to patient outcome and ultimately product development.

Over time, he moved from the large pharmaceutical setting into early-stage biotech, learning firsthand what it takes to advance molecules into the clinic under real uncertainty. Adam said, “I felt like I had trained perfectly for 15 years for a job I didn’t know existed until I started it.”

Today, he oversees programs that aim not just to generate signals, but to deliver durable benefit for thousands on oncology patients.

Seeing ALS through an oncologist’s lens

The ALS field, Adam explained, feels fundamentally different than oncology, not because of lack of effort, but because of where the field is on the maturity curve.

In cancer, decades of investment in genetics, biomarkers, mechanistic biology and interventions have created a framework where preclinical and early-stage data can meaningfully predict downstream impact. Patients enrolling in clinical trials are often told, credibly, that there is a reasonable chance a drug could help them. In many cases, it does.

By contrast, Adam said that when he examined the data behind current ALS therapies and trials, the gap was stark. Signals that would not survive scrutiny in oncology are often the best available options in neurodegeneration. Participation in trials still matters deeply, but the expectation today is more about advancing the field than delivering near-term personal benefit.

He explained, “The best expectation is that you’re going to advance the field, but not likely get any personal benefit yet.”

That realization, he said, was sobering. It also clarified the work ahead.

When the disease enters your family

As an MD-PhD, Adam quickly came to understand ALS at the molecular level. As a son, he has lived alongside its progression.

He described how his understanding shifted from focusing on disease-modifying potential to prioritizing quality of life. While no therapy can yet stop the disease, symptom management, anticipatory care, and honest communication can still make a meaningful difference.

Adam spoke about the importance of clinicians who walk families through what may come next, not with false hope, but with preparedness. Knowing what symptoms might emerge, and knowing there are ways to manage them, can reduce fear and restore a sense of agency.

Emotionally, the adjustment was real. His mother, once highly social, began spending less time out and about. Speech became harder. Mobility increasingly required assistance. These changes are not theoretical, and they are not gradual in the way families wish they would be.

Genetics, knowledge, and hard questions

Adam also reflected on the complicated role of genetics in ALS. While only a minority of cases are driven by known genetic variants, those insights matter enormously for understanding disease mechanisms. He explained, “You need to understand the pathophysiology at the molecular level to treat the disease. Genetics is the first insight into that.”

At the same time, he said that genetic knowledge comes with emotional weight. Testing can raise questions not only about treatment options, but about risk for children and future generations. In oncology, genes like BRCA reshaped the management of disease when targeted therapies were approved, but only after years of painful uncertainty.

ALS, he said, is earlier in that journey. Genetics will be part of the answer, but not the whole one. Still, understanding disease biology at a molecular level is non-negotiable if effective treatments are ever to emerge.

Why Target ALS matters

Before ALS touched his own family, Adam knew of Target ALS through personal connections to Dan Doctoroff. What stood out to him, once he engaged more deeply, was not a single project or program, but the structure being built underneath the science.

He said what Target ALS is assembling looks like the foundation that enabled progress in oncology: shared resources, collaborative data platforms, and deep investment in enabling technologies like genomics and proteomics. Rather than isolated bets, it is an ecosystem designed to let many ideas advance faster.

From his vantage point, that approach is not optional. History suggests it is the only path that has ever worked at scale.

Related News

Before it had a name

May 26, 2026

Impossible Is Not an Option

May 26, 2026

Dear Dad

May 21, 2026

All In for Margy

May 7, 2026